Telix Pharmaceuticals Limited (OTCPK:TLPPF) H1 2025 Earnings Conference Call August 20, 2025 7:30 PM ET
Company Participants
Christian P. Behrenbruch – Co-Founder, MD, Group CEO & Executive Director
Darren Smith – Group Chief Financial Officer
Kevin Richardson – Chief Executive Officer of Telix Precision Medicine
Kyahn Williamson – Senior Vice President of Corporate Communications & Investor Relations
Richard Valeix – Chief Executive Officer of Telix Therapeutics
Conference Call Participants
David A. Low – JPMorgan Chase & Co, Research Division
David Matthew Nierengarten – Wedbush Securities Inc., Research Division
John Hester – Bell Potter Securities Limited, Research Division
Nicholas Lorusso – TD Cowen, Research Division
Tsan-Yu Hsieh – William Blair & Company L.L.C., Research Division
Xiaochuan Dai – UBS Investment Bank, Research Division
Operator
Thank you for standing by, and welcome to the Telix Half Quarter 2025 Results and Investor Webcast. [Operator Instructions]
I would now like to hand the conference over to Ms. Kyahn Williamson. Please go ahead.
Kyahn Williamson
Thank you and everybody, for joining us this morning and this evening for those joining from overseas. My name is Kyahn Williamson. I’m the SVP of Investor Relations and Corporate Communications at Telix. You can see there our disclaimer.
Just moving forward to Slide 4. I’d like to introduce today’s speakers that are on the line with me. We have Chris Behrenbruch, our Group CEO and Managing Director; Darren Smith, our Group Chief Financial Officer; Kevin Richardson, CEO of Telix Precision Medicine; and Richard Valeix, CEO of Telix Therapeutics.
Today, we’ll be taking you through the H1 2025 financial results presentation lodged earlier today on the ASX and our operational achievements for the half. This call is scheduled to run for 1 hour. And following the presentation, we’ll take questions firstly from analysts on the phone and request that you ask one question at
#Telix #Pharmaceuticals #Limited #TLPPF #Earnings #Call #Transcript